Our data demonstrate that I-DXd selectively eliminates pro-tumor VEGFA+ TANs with high CSF3 expression within the TME, mitigating the potential counterproductive effects of G-CSF and enhancing the immunomodulatory impact of ADC therapy. This evidence concerns the gene VEGFA and neoplasm.